The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors

  • E. A. Emini
  • V. W. Byrnes
  • J. H. Condra
  • W. A. Schleif
  • V. V. Sardana
Conference paper
Part of the Archives of Virology Supplementum book series (ARCHIVES SUPPL, volume 9)


The nonnucleoside reverse transcriptase (RT) inhibitors are structurally diverse compounds that are specific inhibitors of the human immunodeficiency virus type 1 RT enzyme. The compounds are largely functionally identical and bind to a common site in the enzyme. HIV-1 variants that exhibit reduced susceptibility to these inhibitors have been derived in cell culture and, more recently, from HIV-1-infected patients undergoing experimental therapy. The variants express amino acid substitutions at RT positions that apparently interact directly with the inhibitors. Effects of specific substitutions at these positions vary among the compounds, suggesting subtle differences in how the compounds physically interact with the enzyme.


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Nonnucleoside Inhibitor Human Immunodeficiency Virus Reverse Transcriptase Nucleoside Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome ( AIDS ). Science 220: 868–871Google Scholar
  2. 2.
    Popovic M, Sarngadharan MG, Read E, Gallo R (1984) Detection, isolation, and continuous production of cytopathic retroviruses ( HTLV-III) from patients with AIDS and pre-AIDS. Science 224: 497–500PubMedCrossRefGoogle Scholar
  3. 3.
    Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D, AZT Collaborative Working Group (1987) The efficacy of azidothymidine ( AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317: 185–191Google Scholar
  4. 4.
    Butler KM, Husso RN, Balis FM, Brouwers P, Eddy J, El-Amin D, Gress J, Hawkins M, Jarosinski P, Moss H, Poplack D, Santacroce S, Venzon D, Wiener L, Wolters P, Pizzo PA (1991) Dideoxyinosine in children with symptomatic human immunodeficiency virus syndrome. N Engl J Med 324: 137–144PubMedCrossRefGoogle Scholar
  5. 5.
    Larder BA, Darby G, Richman DD (1989) HIV with reduced sensitivity to Zidovudine ( AZT) isolated during prolonged therapy. Science 243: 1731–1734Google Scholar
  6. 6.
    Boucher CAB, Tersmette M, Lange JMA, Kellam P, deGoede REY, Mulder JW, Darby G, Goudsmit J, Larder BA (1990) Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 336: 585–590PubMedCrossRefGoogle Scholar
  7. 7.
    Land S, Treloar G, McPhee D, Birch C, Doherty R, Cooper D, Gust I (1990) Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J Infect Dis 161: 326–329PubMedCrossRefGoogle Scholar
  8. 8.
    Richmann DD, Grimes JM, Lagakos SW (1990) Effect of stage of disease and drug dose of zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 3: 743–746Google Scholar
  9. 9.
    St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA (1991) Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253: 1557–1559CrossRefGoogle Scholar
  10. 10.
    Goldman ME, Nunberg JH, O’Brien JA, Quintero JC, Schleif WA, Freund KF, Gaul SL, Saari WS, Wai JS, Hoffman JM, Anderson PS, Hupe DJ, Emini EA, Stern AM (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA 88: 6863–6867PubMedCrossRefGoogle Scholar
  11. 11.
    Saari WS, Hoffman JM, Wai JS, Fisher TE, Rooney CS, Smith AM, Thomas CM, Goldman ME, O’Brien JA, Nunberg JH, Quintero JC, Schleif WA, Emini EA, Stern AM, Anderson PS (1991) 2-pyridinone derivatives: a new class of nonnucleoside, HIV-1 specific reverse transcriptase inhibitors. J Med Chem 34: 2922–2925Google Scholar
  12. 12.
    Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih C-K, Eckner K, Hattox S, Adams J, Rosenthal AS, Faanes R, Eckner RJ, Koup RA, Sullivan JL (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250: 1411–1413PubMedCrossRefGoogle Scholar
  13. 13.
    Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, van Gelder J, Woestenborghs R, Heykants J, Schellekens K, Janssen MAC, DeClerq E, Jannsen PA (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343: 470–474PubMedCrossRefGoogle Scholar
  14. 14.
    White EL, Buckheit RW, Ross LJ, Germany JM, Andries K, Pauwels R, Janssen PAJ, Shannon WM, Chirigos MA (1991) A TIBO derivative, R82193, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res 16: 257–266PubMedCrossRefGoogle Scholar
  15. 15.
    Richman D, Rosenthal AS, Skoog M, Eckner RJ, Chou T-C, Sabo JP, Merluzzi VJ (1991) BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 35: 305–308PubMedGoogle Scholar
  16. 16.
    Nunberg JH, Schleif WA, Boots EJ, O’Brien JA, Quintero JC, Hoffman JM, Emini EA, Goldman ME (1991) Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 65: 4887–4892PubMedGoogle Scholar
  17. 17.
    Richman D, Shih C-K, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhib¬itors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 88: 11241–11245PubMedCrossRefGoogle Scholar
  18. 18.
    Cohen KA, Hopkins J, Ingraham RH, Pargellis C, Wu JC, Palladino DEH, Kinkade P, Warren TC, Rogers S, Adams J, Farina PR, Grob PM (1991) Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem 22: 14670–14674Google Scholar
  19. 19.
    Shih C-K, Rose JM, Hansen GL, Wu JC, Bacolla A, Griffin JA (1991) Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptase display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci USA 88: 9878–9882PubMedCrossRefGoogle Scholar
  20. 20.
    Condra JH, Emini EA, Gotlib L, Graham DJ, Schlabach AJ, Wolfgang JA, Colonno RJ, Sardana VV (1992) Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother 36: 1441–1446PubMedGoogle Scholar
  21. 21.
    Sardana VV, Emini EA, Gotlib L, Graham DJ, Lineberger DW, Long WJ, Schlabach AJ, Wolfgang JA, Condra JH (1992) Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J Biol Chem 267: 17526–17530PubMedGoogle Scholar
  22. 22.
    Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256: 1783–1790PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • E. A. Emini
    • 1
  • V. W. Byrnes
    • 1
  • J. H. Condra
    • 1
  • W. A. Schleif
    • 1
  • V. V. Sardana
    • 1
  1. 1.Merck Research LaboratoriesWest PointUSA

Personalised recommendations